Funcom N.V (NO) (OSL:FUNCOM) FUNCOM`S 3RD QUARTER FINANCIAL REPORT FOR 2008
Funcom N.V (NO) (OSL:FUNCOM) Funcom`s 3rd quarter financial report for 2008 can be downloaded from the company`s website, under the page `Investor Relations`.
Funcom N.V (NO) (OSL:FUNCOM) Funcom`s 3rd quarter financial report for 2008 can be downloaded from the company`s website, under the page `Investor Relations`.
Wienerberger AG (WBAG:WIE) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Aker Solutions ASA (OSL:AKVER) 12 November 2008 - Aker Solutions have signed contracts with Murphy Exploration & Production Company - USA (Murphy) to provide subsea trees, control systems and steel tube umbilicals to the company's Gulf of Mexico (GOM) programme. The initial order is worth approximately USD 23 million.
EMGS (OSL:EMGS) Electromagnetic Geoservices ASA's (EMGS) third quarter 2008 results will be released on Thursday 20 November 2008. CEO Terje Eidesmo and CFO Svein Knudsen will present the third quarter results from 0830 CET at Hotel Continental, Stortingsgaten 24, Oslo. Breakfast will be served from 0815.
NOKIA (HEL:NOK) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Statkraft (OSL:STAEN) (Oslo, 12 November 2008) Statkraft has decided to purchase all the remaining shares in the company Catamount Cymru Cyf, which owns the rights to build and operate Blaengwen wind farm in Wales. The purchase is part of Statkraft's wind power focus in Europe. Blaengwen wind farm - which is under construction - will provide clean electricity to 16,000 UK households.
Biovitrum AB (STO:BVT) STOCKHOLM, Sweden and MADISON, New Jersey, USA - November 12, 2008. Biovitrum AB (publ) (STO:BVT) and Wyeth (NYSE:WYE) today announced an extension of the ReFacto® supply agreement until December 31, 2015. Biovitrum will continue to be the sole producer of drug substance for Wyeth for ReFacto®, as well as Xyntha®/ReFacto® AF, the successor products, and will continue to receive royalties from Wyeth's global sales. Biovitrum's co-promotion rights in the Nordic region remain unchanged.